Morgan Mace

Statistics

Publications

Citations

454

H-Index

Active since

2017

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Morgan Mace is an author at The University of Texas MD Anderson Cancer Center specializing in chemotherapy in hematologic malignancies, hematologic malignancy therapy, and hematologic oncology.

ORCID

Publications per year

2017–2018

Publications

Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

Courtney D. DiNardo, Caitlin R. Rausch, Christopher B. Benton et al. · American Journal of Hematology · 2017 · 437 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial

Koji Sasaki, Hagop M. Kantarjian, Farhad Ravandi et al. · Blood · 2018 · 17 citations

Medicine, Hematology, Oncology +17

1–2 of 2